Edition:
India

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,268.00DKK
18 May 2018
Change (% chg)

kr.13.00 (+1.04%)
Prev Close
kr.1,255.00
Open
kr.1,255.00
Day's High
kr.1,268.50
Day's Low
kr.1,254.00
Volume
140,488
Avg. Vol
251,654
52-wk High
kr.1,486.00
52-wk Low
kr.994.80

Latest Key Developments (Source: Significant Developments)

Genmab Says Will Increase Share Capital By 155,576 Shares
Tuesday, 15 May 2018 

May 15 (Reuters) - Genmab A/S ::CAPITAL INCREASE IN GENMAB AS A RESULT OF EMPLOYEE WARRANT EXERCISE.WILL INCREASE ITS SHARE CAPITAL BY 155,576 SHARES AS A CONSEQUENCE OF THE EXERCISE OF EMPLOYEE WARRANTS.INCREASE CORRESPONDS TO APPROX. 0.25 % OF THE COMPANY'S SHARE CAPITAL.TOTAL NOMINAL VALUE OF SHARE CAPITAL AFTER INCREASE IS DKK 61,436,818 CORRESPONDING TO 61,436,818 VOTES.  Full Article

Genmab Q1 Operating Result DKK 324 Million, Below Expectations
Tuesday, 8 May 2018 

May 8 (Reuters) - Genmab A/S ::REG-INTERIM REPORT FIRST QUARTER 2018.REVENUE WAS DKK 681 MILLION IN Q1 OF 2018 COMPARED TO DKK 251 MILLION IN Q1 OF 2017.OPERATING INCOME WAS DKK 324 MILLION IN Q1 OF 2018 COMPARED TO DKK 46 MILLION IN Q1 OF 2017.IS MAINTAINING ITS 2018 FINANCIAL GUIDANCE PUBLISHED ON FEBRUARY 21, 2018..Q1 REVENUE DKK 681 MILLION (REUTERS POLL DKK 684 MILLION).Q1 OPERATING RESULT DKK 324 MILLION (REUTERS POLL DKK 358 MILLION).OPERATING EXPENSES WERE DKK 357 MILLION IN Q1 OF 2018 COMPARED TO DKK 205 MILLION IN Q1 OF 2017.Q1 NET PROFIT DKK 198.6 MILLION (REUTERS POLL DKK 282 MILLION).  Full Article

Genmab gets U.S. FDA approval of Darzalex in newly diagnosed multiple Myeloma
Tuesday, 8 May 2018 

May 7 (Reuters) - Genmab A/S ::REG-GENMAB ANNOUNCES U.S. FDA APPROVAL OF DARZALEX (DARATUMUMAB) IN NEWLY DIAGNOSED MULTIPLE MYELOMA.GENMAB - FDA SUBSEQUENTLY GRANTED PRIORITY REVIEW TO SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION, WITH PRESCRIPTION DRUG USER FEE ACT TARGET DATE OF MAY 21.  Full Article

Genmab: Q1 Net Sales Of Darzalex At $432 Mln
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Genmab A/S ::REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2018.REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2018.NET SALES OF DARZALEX IN Q1 OF 2018 TOTALED USD 432 MILLION.WILL RECEIVE ROYALTIES ON WORLDWIDE SALES FROM JANSSEN BIOTECH, INC.  Full Article

Genmab 2017 Net Sales Of DARZALEX At $1.24 Billion
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - GENMAB ::ANNOUNCES 2017 NET SALES FIGURES FOR DARZALEX® (DARATUMUMAB).‍WORLDWIDE NET SALES OF DARZALEX (DARATUMUMAB) AS REPORTED BY JOHNSON & JOHNSON WERE USD 1,242 MILLION IN 2017​.‍NET SALES WERE USD 884 MILLION IN U.S. AND NET SALES IN REST OF WORLD WERE USD 358 MILLION​.  Full Article

U.S. FDA Grants Priority Review For Daratumumab In Front Line Multiple Myeloma
Saturday, 20 Jan 2018 

Jan 19 (Reuters) - Genmab A/S ::U.S. FDA GRANTS PRIORITY REVIEW FOR DARATUMUMAB IN FRONT LINE MULTIPLE MYELOMA.GENMAB - FDA HAS ASSIGNED PDUFA TARGET DATE OF MAY 21, 2018 TO TAKE A DECISION ON DARATUMUMAB IN THE INDICATION.  Full Article

Gemnab Says Artisan Partners Increased Indirect Ownership In Co To 5.04 Pct Of Share Capital and Voting Rights
Wednesday, 10 Jan 2018 

Jan 9 (Reuters) - Genmab A/S ::GENMAB - ‍ARTISAN PARTNERS INCREASED THEIR INDIRECT OWNERSHIP IN CO TO 3,081,731 SHARES, AMOUNTING TO 5.04% OF SHARE CAPITAL, VOTING RIGHTS IN CO.MAJOR SHAREHOLDER ANNOUNCEMENT.  Full Article

Biotech Genmab sees 2018 expense growth of 40-50 pct
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - FOLLOWING ARE STATEMENTS FROM GENMAB'S R'N'D UPDATE IN ATLANTA, GEORGIA: :DENMARK'S GENMAB SEES 2018 EXPENSE GROWTH OF 40-50 PERCENT DRIVEN BY PIPELINE INVESTMENTS.SAYS ROYALTY FUNDS 100 PCT OF EXPENSE INVESTMENT.GENMAB TO CONDUCT NEW AND LARGER TISOTUMAB VEDOTIN TRIALS IN 2018.SAYS 6 PRE-CLINICAL PRODUCTS RAPIDLY ADVANCING.SAYS 2018 WILL BE 6TH YEAR OF PROFITABILITY.  Full Article

Genmab Achieves $20 Million Milestone In Daratumumab Collaboration With Janssen
Thursday, 30 Nov 2017 

Nov 29 (Reuters) - Genmab A/S ::GENMAB ACHIEVES USD 20 MILLION MILESTONE IN DARATUMUMAB COLLABORATION WITH JANSSEN AND UPDATES FINANCIAL GUIDANCE.GENMAB - EXPECT 2017 REVENUE TO BE IN RANGE OF DKK 2,240 - 2,440 MILLION.GENMAB - PAYMENT RELATES TO PHASE III ANDROMEDA STUDY OF DARATUMUMAB IN COMBINATION WITH CYCLOPHOSPHAMIDE, BORTEZOMIB & DEXAMETHASONE IN AMYLOIDOSIS.  Full Article

Genmab: $50 mln milestone payment in collaboration on Darzalex
Friday, 17 Nov 2017 

Nov 17(Reuters) - GENMAB A/S : :SAID ON FRIDAY WILL RECEIVE MILESTONE PAYMENT OF USD 50 MILLION IN DARZALEX COLLABORATION WITH JANSSEN BIOTECH, INC..SAID MILESTONE TRIGGERED BY SALES OF DARZALEX REACHING USD 1 BILLION IN A CALENDAR YEAR.THE MILESTONE WAS INCLUDED IN GENMAB’S 2017 FINANCIAL GUIDANCE PUBLISHED ON NOVEMBER 14, 2017.  Full Article

BRIEF-Genmab: Q1 Net Sales Of Darzalex At $432 Mln

* REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2018